Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases.
Hazafa. Abu A; Batool. Ammara A; Ahmad. Saeed S; Amjad. Muhammad M; Chaudhry. Sundas Nasir SN; Asad. Jamal J; Ghuman. Hasham Feroz HF; Khan. Hafiza Madeeha HM; Naeem. Muhammad M; Ghani. Usman U
Key Findings
- Humanin protects various cell types from stress‑induced apoptosis via pathways like JAK/STAT and BCL‑2 interactions.
- In animal and cell studies, humanin reduced damage in bone loss, cardiovascular disease, diabetes, and neurodegenerative models.
- Humanin appears to boost the cancer‑killing effects of TNF‑α, suggesting a possible anti‑cancer role.
Practical Outcomes
- At this stage humanin is a promising research target but not ready for DIY supplementation. Enthusiasts should watch for future clinical trials that define safe doses and delivery methods before considering it for longevity or health‑optimization protocols.
Summary
Humanin is a tiny protein made by mitochondria that helps protect cells from stress and death. Research shows it can reduce cell loss in conditions like osteoporosis, heart disease, diabetes, and brain disorders, and it might even help kill cancer cells. However, the studies are mostly early‑stage and don’t give clear dosing or safety info for everyday use.
Abstract
Humanin (HN) is a small mitochondrial-derived cytoprotective polypeptide encoded by mtDNA. HN exhibits protective effects in several cell types, including leukocytes, germ cells, neurons, tissues against cellular stress conditions and apoptosis through regulating various signaling mechanisms, such as JAK/STAT pathway and interaction of BCL-2 family of protein. HN is an essential cytoprotective peptide in the human body that regulates mitochondrial functions under stress conditions. The present review aims to evaluate HN peptide's antiapoptotic activities as a potential therapeutic target in the treatment of cancer, diabetes mellitus, male infertility, bone-related diseases, cardiac diseases, and brain diseases. Based on in vitro and in vivo studies, HN significantly suppressed the apoptosis during the treatment of bone osteoporosis, cardiovascular diseases, diabetes mellitus, and neurodegenerative diseases. According to accumulated data, it is concluded that HN exerts the proapoptotic activity of TNF-α in cancer, which makes HN as a novel therapeutic agent in the treatment of cancer and suggested that along with HN, the development of another mitochondrial-derived peptide could be a viable therapeutic option against different oxidative stress and apoptosis-related diseases.
Study Information
pubmed
2020
2020-10-29T00:00:00.000Z
10.1016/j.lfs.2020.118679
81
127